These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17674329)

  • 1. Persistence of cell-mediated immunity to vaccinia virus.
    Kim SH; Oh MD
    J Infect Dis; 2007 Sep; 196(5):805-6. PubMed ID: 17674329
    [No Abstract]   [Full Text] [Related]  

  • 2. The persistence of humoral and cellular immunities more than three decades after smallpox vaccination.
    Kim SH; Yeo SG; Park KH; Bang JW; Kim HB; Kim NJ; Jee Y; Cho H; Oh MD; Choe KW
    Clin Microbiol Infect; 2007 Jan; 13(1):91-3. PubMed ID: 17184294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of residual immunity to smallpox, by means of an intradermal skin test with inactivated vaccinia virus.
    Kim SH; Bang JW; Park KH; Park WB; Kim HB; Kim NJ; Jee Y; Cho H; Oh MD; Choe KW
    J Infect Dis; 2006 Aug; 194(3):377-84. PubMed ID: 16826487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of immunity to vaccinia virus by using diluted inactivated vaccinia vaccine solution for skin testing.
    Somekh E; Smetana Z; Tanay A; Dalal I; Babai I; Mendelson E
    Vaccine; 2004 Dec; 23(3):321-4. PubMed ID: 15530675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune responses to vaccinia and influenza elicited during primary versus recent or distant secondary smallpox vaccination of adults.
    Treanor J; Wu H; Liang H; Topham DJ
    Vaccine; 2006 Nov; 24(47-48):6913-23. PubMed ID: 17014939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New data in a 200-year investigation.
    Bray M
    Clin Infect Dis; 2004 Jan; 38(1):90-1. PubMed ID: 14679453
    [No Abstract]   [Full Text] [Related]  

  • 7. [Experiments on the challenge of the antivaccinial transfer immunity of cell cultures by infection with variola virus. (Evaluation of the antivariola potency of smallpox vaccines)].
    Stickl H
    Zentralbl Bakteriol Orig; 1968; 208(4):473-85. PubMed ID: 4329545
    [No Abstract]   [Full Text] [Related]  

  • 8. Bioterrorism. Smallpox vaccinations: how much protection remains?
    Cohen J
    Science; 2001 Nov; 294(5544):985. PubMed ID: 11691969
    [No Abstract]   [Full Text] [Related]  

  • 9. Age distribution for T cell reactivity to vaccinia virus in a healthy population.
    Hsieh SM; Pan SC; Chen SY; Huang PF; Chang SC
    Clin Infect Dis; 2004 Jan; 38(1):86-9. PubMed ID: 14679452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified vaccinia Ankara: potential as an alternative smallpox vaccine.
    McCurdy LH; Larkin BD; Martin JE; Graham BS
    Clin Infect Dis; 2004 Jun; 38(12):1749-53. PubMed ID: 15227622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detailed kinetics of immune responses to a new cell culture-derived smallpox vaccine in vaccinia-naïve adults.
    Kim SH; Choi SJ; Park WB; Kim HB; Kim NJ; Oh MD; Choe KW
    Vaccine; 2007 Aug; 25(33):6287-91. PubMed ID: 17597266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Smallpx vaccination].
    Just M
    Schweiz Med Wochenschr; 1968 Mar; 98(13):495-503. PubMed ID: 5700509
    [No Abstract]   [Full Text] [Related]  

  • 13. IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.
    Jones T
    Curr Opin Mol Ther; 2008 Aug; 10(4):407-17. PubMed ID: 18683106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
    Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
    Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine.
    Ferrier-Rembert A; Drillien R; Tournier JN; Garin D; Crance JM
    Vaccine; 2008 Mar; 26(14):1794-804. PubMed ID: 18336966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive treatments reduce long-term immunity to smallpox among patients with breast cancer.
    Wiser I; Orr N; Kaufman B; Segev S; Smetana Z; Bialik A; Epstein N; Mendelson E; Catane R; Cohen D
    J Infect Dis; 2010 May; 201(10):1527-34. PubMed ID: 20388035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of vaccination immunity in hospital personnel revaccinated at three-year intervals.
    Nyerges G; Hollós I; Losonczy G; Erdös L; Petrás G
    Acta Microbiol Acad Sci Hung; 1972; 19(1):63-8. PubMed ID: 4651044
    [No Abstract]   [Full Text] [Related]  

  • 18. Serological Immunity to Smallpox in New South Wales, Australia.
    Costantino V; Trent MJ; Sullivan JS; Kunasekaran MP; Gray R; MacIntyre R
    Viruses; 2020 May; 12(5):. PubMed ID: 32443405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of vaccinia at the site of smallpox vaccination.
    Cummings JF; Polhemus ME; Hawkes C; Klote M; Ludwig GV; Wortmann G
    Clin Infect Dis; 2008 Jan; 46(1):101-2. PubMed ID: 18171221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
    Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
    J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.